The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2020 | Updates from AMG 330 in AML
Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, updates us on the use of AMG 330, a novel bispecific T-cell engager antibody construct in relapsed/refractory acute myeloid leukemia (AML), as well as efforts being made to mitigate the incidence of cytokine release syndrome. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
